{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:40Z","timestamp":1792154560025,"version":"4.4.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2019.01313","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T02:14:28Z","timestamp":1575944068000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy"],"prefix":"10.3389","volume":"10","author":[{"given":"Kerstin A.","family":"Klotz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta","family":"Metternich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schulze-Bonhage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"J Epilepsy Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1111\/epi.14477","article-title":"Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results","volume":"59","author":"Szaflarski","year":"2018","journal-title":"Epilepsia."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/acn3.621","article-title":"A prospective open-label trial of a CBD\/THC cannabis oil in dravet syndrome","volume":"5","author":"McCoy","year":"2018","journal-title":"Ann Clin Transl Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1111\/bcp.14038","article-title":"A systematic review of cannabidiol dosing in clinical populations","volume":"85","author":"Millar","year":"2019","journal-title":"Br J Clin Pharmacol."},{"key":"B9","unstructured":"Press Announcements\u2014FDA Approves First Drug Comprised of an Active Ingredient Derived From Marijuana to Treat Rare, Severe Forms of Epilepsy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/09540261.2018.1474730","article-title":"Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches","volume":"30","author":"Bonn-Miller","year":"2018","journal-title":"Int Rev Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"Br J Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40263-019-00624-4","article-title":"Pharmacokinetics and tolerability of multiple doses of pharmaceutical-grade synthetic cannabidiol in pediatric patients with treatment-resistant epilepsy","volume":"33","author":"Wheless","year":"2019","journal-title":"CNS Drugs."},{"key":"B13","unstructured":"ZynerbaTop-Line Results from Phase 2 STAR 1 Trial of ZYN002 in Adult Epilepsy Patients with Focal Seizures2017"},{"key":"B14","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/WNP.0b013e318175d472","article-title":"Guideline twelve: guidelines for long-term monitoring for epilepsy","volume":"25","year":"2008","journal-title":"J Clin Neurophysiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","article-title":"Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US","volume":"33","author":"Sands","year":"2019","journal-title":"CNS Drugs."},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yebeh.2018.07.020","article-title":"Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study","volume":"87","author":"Szaflarski","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/epi.14608","article-title":"Cannabis-based products for pediatric epilepsy: a systematic review","volume":"60","author":"Elliott","year":"2019","journal-title":"Epilepsia."},{"key":"B20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/epi.14670","article-title":"Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study","volume":"60","author":"Thiele","year":"2019","journal-title":"Epilepsia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40263-018-0550-4","article-title":"Cannabinoid-based therapies and brain development: potential harmful effect of early modulation of the endocannabinoid system","volume":"32","author":"Schonhofen","year":"2018","journal-title":"CNS Drugs."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"interactions between cannabidiol and commonly used antiepileptic drugs","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.1111\/epi.16071","article-title":"Effects of cannabidiol on brivaracetam plasma levels","volume":"60","author":"Klotz","year":"2019","journal-title":"Epilepsia."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.yebeh.2012.04.128","article-title":"Seizure diaries for clinical research and practice: limitations and future prospects","volume":"24","author":"Fisher","year":"2012","journal-title":"Epilepsy Behav."},{"key":"B26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11910-018-0882-y","article-title":"Cannabis for the treatment of epilepsy: an update","volume":"18","author":"Gaston","year":"2018","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front Neurol."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01313\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T02:14:30Z","timestamp":1575944070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2019.01313\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":27,"alternative-id":["10.3389\/fneur.2019.01313"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2019.01313","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,10]]},"article-number":"1313"}}